SOP Guide for Pharma

Analytical Method Development: Solvent Selection for NMR – V 2.0

Auditor

Analytical Method Development: Solvent Selection for NMR – V 2.0

Standard Operating Procedure for Solvent Selection for NMR in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/113/2025
Supersedes SOP/AMD/113/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP defines the criteria and procedure for selecting appropriate deuterated solvents for NMR analysis, ensuring optimal solubility, minimal spectral interference, chemical inertness, and consistent peak assignment in pharmaceutical method development.

2. Scope

This SOP applies to all NMR studies involving APIs, intermediates, excipients, impurities, and degradation products conducted in the Analytical Method Development (AMD) laboratory, covering both 1D and 2D NMR techniques.

3. Responsibilities

  • NMR Analyst: Conducts solubility screening, selects appropriate solvents, and records final choice.
  • Method Developer: Reviews solvent selection with respect to analytical goals and sample compatibility.
  • QA Officer: Ensures that solvent-related documentation meets GLP and regulatory expectations.
  • Head – AMD: Approves final solvent list and confirms control of hazardous materials.
See also  Analytical Method Development: SOP for DSC Method for Thermal Behavior Analysis - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring safe, scientifically sound, and well-documented solvent selection for all NMR activities.

5. Procedure

5.1 Initial Screening and Solubility Testing

  1. Perform a visual solubility check in at least two common deuterated solvents:
    • CDCl3 (non-polar)
    • DMSO-d6 (polar aprotic)
    • CD3OD (polar protic)
    • D2O (aqueous)
  2. Dissolve 5–10 mg of sample in 0.6 mL solvent and vortex or sonicate.
  3. Assess visually for full dissolution, turbidity, or precipitation.
  4. Record observations in Annexure-1: Solubility Screening Log.

5.2 Compatibility Assessment

  1. Review chemical stability of the compound in the selected solvent:
    • Avoid D2O if compound is hydrolytically sensitive.
    • Avoid CDCl3 if compound is acid-labile due to trace HCl formation.
  2. Check for:
    • Exchangeable protons (NH, OH) in D2O may not appear in 1H NMR.
    • Overlapping solvent peaks with analyte signals.
  3. Log compatibility notes in Annexure-2: Solvent Compatibility Review.

5.3 Spectral Considerations

  1. Ensure the solvent peak does not overlap with the region of interest:
    • CDCl3: 7.26 ppm
    • DMSO-d6: 2.50 ppm
    • CD3OD: 3.31 ppm
    • D2O: Suppressed
  2. Consider use of solvent suppression techniques if unavoidable overlaps occur.
  3. For 13C NMR, account for natural abundance splitting of solvent signals.
  4. Record solvent-related peak interference in Annexure-3: Spectral Interference Log.
See also  Analytical Method Development: SOP for Analytical Method for Liposomes - V 2.0

5.4 Final Solvent Selection

  1. Choose the solvent with:
    • Complete solubility of sample
    • No degradation over 2 hours at room temperature
    • Minimal peak overlap in regions of interest
  2. Document solvent justification in Annexure-4: Final Solvent Justification Sheet.
  3. Store selected solvent under dry, inert conditions and label NMR tubes with solvent used.

5.5 Safety Considerations

  1. Refer to MSDS for each deuterated solvent and ensure lab personnel wear gloves and goggles.
  2. Label all NMR waste and dispose through authorized vendor for halogenated solvents (e.g., CDCl3).
  3. Maintain safety log in Annexure-5: Solvent Safety and Disposal Record.

6. Abbreviations

  • NMR: Nuclear Magnetic Resonance
  • CDCl3: Deuterated Chloroform
  • DMSO-d6: Deuterated Dimethyl Sulfoxide
  • CD3OD: Deuterated Methanol
  • D2O: Deuterium Oxide
  • MSDS: Material Safety Data Sheet

7. Documents

  1. Solubility Screening Log – Annexure-1
  2. Solvent Compatibility Review – Annexure-2
  3. Spectral Interference Log – Annexure-3
  4. Final Solvent Justification Sheet – Annexure-4
  5. Solvent Safety and Disposal Record – Annexure-5
See also  Analytical Method Development: SOP for DLS Method for Nanoparticle Size Analysis - V 2.0

8. References

  • ICH Q6A – Specifications
  • USP <761> – NMR Spectroscopy
  • Solvent Chemical Compatibility Database (Sigma-Aldrich)

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Solubility Screening Log

Sample Solvent Solubility Result Remarks
API-113 DMSO-d6 Complete Preferred solvent
API-113 CDCl3 Partial Cloudy solution

Annexure-2: Solvent Compatibility Review

DMSO-d6 confirmed chemically inert; no degradation over 2 hours. CDCl3 showed minor discoloration due to API reactivity.

Annexure-3: Spectral Interference Log

Solvent Solvent Peak (ppm) Overlap With Analyte? Conclusion
DMSO-d6 2.50 No Acceptable

Annexure-4: Final Solvent Justification Sheet

DMSO-d6 selected based on full solubility, no degradation, and no interference with signals of interest.

Annexure-5: Solvent Safety and Disposal Record

Solvent Hazard Class Used Volume Disposal Method Date
CDCl3 Toxic 20 mL Hazardous Waste Collection 18/05/2025

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Expanded solvent list and added spectral overlap annexure Annual Review
Exit mobile version